Dianthus Therapeutics DNTH Income Statement
| Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| —— | $396K-81.8% | $193K-89.6% | $1.16M+33.1% | $1.33M+190% | ||
| $34.53M+27.9% | $32.49M+27.2% | $26.25M+45.3% | $27M+106% | $31.21M+255% | ||
| $12.47M+69.9% | $8.2M+25.5% | $8.87M+47.9% | $7.34M+30.1% | $6.83M+47.4% | ||
| $47M+36.9% | $40.68M+26.9% | $35.12M+45.9% | $34.34M+83.5% | $33.24M+148% | ||
| -$46.53M-40.3% | -$40.29M-34.7% | -$34.93M-57.3% | -$33.18M-85.9% | -$31.92M-146% | ||
| $5.7M+55.5% | $3.52M-25.5% | $3.3M-28.3% | $3.67M-10.5% | $3.48M+45.3% | ||
| -$40.83M-38.4% | -$36.77M-46.0% | -$31.63M-79.6% | -$29.51M-115% | -$28.44M-169% | ||
| -$0.85-3.7% | -$0.97-31.1% | -$0.88-72.5% | -$0.82-51.9% | -$0.82— | ||
| -$46.5M-40.3% | -$40.26M-34.8% | -$34.9M-57.3% | -$33.15M-86.0% | -$31.89M-147% | ||
| -$46.53M-40.3% | -$40.29M-34.7% | -$34.93M-57.3% | -$33.18M-85.9% | -$31.92M-146% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Dianthus Therapeutics profitable?
- Dianthus Therapeutics is not currently profitable: it reported a net loss of $138.7M over the trailing twelve months, a -4104.8% net margin.
- What is Dianthus Therapeutics's earnings per share?
- Dianthus Therapeutics's diluted EPS over the trailing twelve months is $-3.52.
- Where does Dianthus Therapeutics's income statement data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.